Top AI Oncology Startups in Europe: Hiring Needs 2026

AI oncology has moved from research promise to a hiring-critical commercial category. The use of technology in healthcare is now directly shaping cancer detection, patient stratification, drug discovery and treatment decision support, creating intense demand for hybrid talent across machine learning, oncology, diagnostics, clinical validation and regulation.

For CTOs, HR Directors, COOs, founders and board members, the core issue in 2026 is not whether the market is growing. It is whether AI oncology startups in Europe can secure the people required to reach clinical validation, CE marking, commercial partnerships and the next funding milestone before competitors do.

This guide maps the European AI oncology startup ecosystem, highlights leading companies and outlines the roles, salary benchmarks and recruitment strategies that matter for 2026 hiring plans.

The European AI Oncology Startup Landscape in 2026

The AI oncology startup ecosystem covers companies applying artificial intelligence to cancer diagnostics, computational oncology, digital pathology, liquid biopsy, genomic assays, companion diagnostics, immuno-oncology and AI-enabled drug discovery. These are not standard software businesses. They operate at the intersection of regulated medical technology, clinical science and advanced data infrastructure.

Across the UK, France, Spain, the Netherlands and Belgium, more than 20 AI oncology startups have been founded or materially scaled since 2020. Cambridge, Barcelona and Paris stand out as primary hubs because they combine cancer research institutions, university spinouts, specialist investors and senior technical talent with prior exposure to medical AI or biotech commercialisation.

The strongest sub-sectors in 2026 include digital pathology for oncology, liquid biopsy, companion diagnostics, computational drug discovery and immuno-oncology. Each has different hiring needs. Digital pathology companies need computer vision and computational pathology expertise. Liquid biopsy businesses require bioinformatics, molecular diagnostics and assay development talent. AI drug discovery firms compete for ML research engineers, computational chemists and translational science leaders.

Strong venture investment has created a simultaneous scaling problem. Multiple startups are trying to hire the same narrow group of senior people at the same time, often immediately after seed, Series A or Series B funding. This is increasing competition for passive candidates who are already employed by pharma, diagnostics companies, research institutes or better-funded scaleups.

Regulation is also changing the hiring equation. The EU MDR and IVDR framework affects diagnostics, companion diagnostics and software used in medical decision-making. The EU AI Act adds further obligations for high-risk AI systems, with many medical AI applications facing higher governance expectations as enforcement phases progress, including key high-risk obligations from August 2026.

Structured summary: Europe’s AI oncology market is expanding quickly, but hiring complexity is rising just as fast. The companies best placed to scale in 2026 will be those that treat recruitment as a strategic function covering technical depth, clinical credibility, regulatory readiness and cross-border talent access.

Top AI Oncology Startups in Europe and Their Hiring Profiles

The following profiles reflect the range of top AI oncology companies in Europe in 2026 and the hiring patterns boards should expect. Funding figures are based on reported or announced rounds referenced in the market and should be treated as directional rather than a substitute for live due diligence.

United Kingdom

• Biofidelity, Cambridge: Biofidelity operates in molecular diagnostics and has positioned its platform around high-sensitivity cancer mutation detection, including reported sensitivity improvements over FDA-approved PCR methods. Its hiring needs are strongest in molecular diagnostics engineering, assay development, regulatory affairs and quality systems.
• Cyted Health, Cambridge: Cyted Health focuses on digital pathology and oesophageal cancer detection, with a reported £13.4M Series A. Typical hiring priorities include computational pathology scientists, clinical affairs managers, pathology workflow specialists and validation-focused ML profiles.
• CHARM Therapeutics, London: CHARM Therapeutics applies AI to drug discovery for solid tumours and has reported a £59.4M Series B. It is likely to compete for ML engineers, computational chemists, structural biology specialists and translational research leaders.
• Curve Therapeutics, Cambridge: Curve Therapeutics works in small molecule drug discovery and has reported a £40.5M Series A. Priority roles include computational biologists, research scientists, platform engineers and senior discovery leaders.
• Spotlight Pathology, Manchester: Spotlight Pathology is focused on AI for blood cancer diagnosis. Its hiring profile is concentrated around digital pathology engineers, clinical AI specialists, haematopathology-aware data scientists and software engineers who can work in regulated clinical environments.

France

• Bioptimus, Paris: Bioptimus is developing universal AI foundation models for biology and has reported a $76M Series A. Hiring demand is strongest for ML research engineers, foundation model specialists, computational pathology scientists and senior data infrastructure talent.
• Orakl Oncology, Villejuif: Orakl Oncology works with patient tumour avatars and has reported a €15M seed round. Its recruitment needs include computational oncologists, bioinformaticians, translational scientists and clinical collaboration leads.
• Cure51, Paris: Cure51 focuses on exceptional cancer responder analysis and has reported €15M in funding. Key hires include computational biologists, data scientists, oncology data engineers and scientific programme leaders.

Spain and Belgium

• REVEAL Genomics, Barcelona: REVEAL Genomics develops HER2DX genomic assays and has reported €6.25M in funding. Its hiring priorities include bioinformaticians, regulatory affairs specialists, clinical evidence professionals and commercial diagnostics talent.
• The Blue Box, Barcelona: The Blue Box is building AI-enabled urine-based breast cancer screening and has reported a €3M seed round. Hiring needs include ML engineers, clinical affairs managers, product leaders and validation-focused data scientists.
• Lucid, Leuven: Lucid works in mammography and breast imaging AI and has reported €4M in funding. It is likely to prioritise computer vision engineers, regulatory specialists, clinical validation leads and AI product managers.

Structured summary: The hiring profile of European oncology AI companies depends on their modality. Diagnostics firms need regulatory and clinical affairs depth. Digital pathology companies need computational pathology and computer vision. AI drug discovery startups need ML, computational biology and translational science leadership. A generic AI recruitment strategy will miss these differences.

Most In-Demand Roles Across European AI Oncology Startups

AI oncology startup recruitment in Europe is now defined by scarcity in hybrid roles. The best candidates rarely sit neatly in one discipline. They understand model performance, clinical context, data quality, regulatory evidence and how research decisions affect commercial timelines.

Computational Pathology Scientists

Computational pathology scientists are among the fastest-growing and smallest-supply profiles. They combine pathology knowledge, image analysis, computer vision and clinical validation awareness. Demand is strongest in Cambridge, Paris, Leuven and other imaging-adjacent hubs. For more context on related imaging shortages, see Optima’s report on the AI medical imaging talent shortage in Europe.

ML Engineers With Oncology Domain Knowledge

ML engineers are available across Europe, but oncology-aware ML engineers are scarce. Startups need people who can work with noisy clinical data, limited labels, survival outcomes, genomic features or histopathology images. The strongest oncology AI engineer jobs in Europe in 2026 will reward candidates who can move beyond experimentation into validated, auditable systems.

Bioinformaticians With Cancer Genomics Specialisation

Bioinformaticians remain critical for liquid biopsy, companion diagnostics, genomic assays and patient stratification. Cambridge, Barcelona and Paris are particularly competitive markets because they combine academic cancer genomics, biotech companies and venture-backed diagnostics firms.

Regulatory Affairs and Clinical Affairs Managers

Regulatory Affairs Managers with EU MDR, IVDR, CE marking and EU AI Act awareness are in acute shortage. Clinical Affairs Managers with oncology trial experience are equally competitive, especially where a startup must build clinical evidence for diagnostic performance, analytical validity or companion diagnostic use.

CSO and VP R&D

CSO and VP R&D searches are increasingly handled through retained executive search because the candidate pool is small, confidential and heavily passive. Boards need leaders who can translate science into milestones investors and regulators recognise.

Structured summary: The most in-demand roles sit at the boundary of AI, oncology and regulation. Hiring success depends on accurately defining which hybrid capabilities are essential and which can be developed after hire.

Hiring Challenges Specific to AI Oncology Startups

The talent shortage in oncology AI is not simply a volume issue. It is a timing, credibility and risk issue. Several well-funded startups may approach the same senior ML engineer, bioinformatician or regulatory leader within the same quarter.

Simultaneous Competition for the Same Candidates

Series A and B companies are often hiring the same profiles at the same time. Candidates with oncology, clinical AI or diagnostics experience may receive approaches from startups, pharma innovation units, medtech companies and AI platform vendors. Early engagement is essential because active applicants represent only a small part of the market.

Regulatory Complexity Raises the Hiring Bar

EU MDR companion diagnostic expectations, IVDR evidence requirements and EU AI Act governance are increasing the complexity of role design. AI oncology diagnostics companies hiring in Europe need candidates who understand documentation, traceability, clinical performance claims, validation and post-market responsibilities.

Pharma and Big Tech Competition

Early-stage oncology AI companies compete with Roche, AstraZeneca, Novartis and other pharma groups for many of the same profiles. Pharma can usually offer higher cash compensation, stronger infrastructure and lower career risk. Startups must therefore compete through mission, scientific ownership, equity upside and speed of decision-making.

Clinical Validation Timelines

Clinical validation can take longer than candidates expect. If milestones are unclear, senior candidates may question whether the company can reach trials, partnerships, reimbursement or commercial deployment. This is particularly relevant for liquid biopsy hiring and companion diagnostics teams where regulatory and clinical evidence pathways are central.

Structured summary: AI oncology hiring is difficult because the candidate pool is narrow, the regulatory burden is rising and well-funded employers are competing for the same individuals. Startups that cannot explain their clinical pathway, funding runway and role impact will lose candidates to lower-risk alternatives.

Salary Benchmarks for AI Oncology Startup Roles in Europe (2026)

Salary benchmarking in oncology AI must account for country, funding stage, seniority, regulatory exposure and whether the role is research, product, clinical or executive. The ranges below are indicative 2026 base salary bands for permanent hires and should be validated against live market data before offer stage.

• Senior ML engineer or computational biology engineer: UK £85,000 to £130,000, France €75,000 to €115,000, Spain €60,000 to €95,000, Belgium €70,000 to €110,000.
• Principal ML, staff engineer or lead computational biologist: UK £120,000 to £165,000, France €105,000 to €150,000, Spain €90,000 to €125,000, Belgium €100,000 to €145,000.
• Regulatory Affairs Manager or Clinical Affairs Manager: UK £75,000 to £120,000, France €80,000 to €130,000, Spain €65,000 to €105,000, Belgium €75,000 to €120,000.
• CSO, VP R&D or senior scientific executive: UK £150,000 to £240,000, mainland Europe €150,000 to €250,000, with equity varying significantly by stage and mandate.

Equity matters, but candidates benchmark it carefully. A Series A startup may need to offer meaningful option participation to offset lower cash compensation than pharma. Senior individual contributors may expect a smaller but still credible grant. VP-level and CSO candidates will scrutinise dilution, strike price, vesting, liquidation preferences and the probability of the next financing event.

Geography also matters. UK and France often price higher for senior AI and regulatory talent, while Spain can be more cost-efficient but increasingly competitive in Barcelona. Belgium is attractive for medtech, imaging and life science expertise, but the senior pool is not large. Cross-border hiring can widen access, but employers must align employment model, tax, benefits and remote expectations.

To compete against established pharma, startups should avoid relying on salary alone. They need clear equity logic, fast decision cycles, genuine scientific ownership, publication or conference flexibility where appropriate, and credible leadership. For senior leadership searches, Optima’s tech executive search guide explains why compensation advisory is often part of the search itself.

Structured summary: AI oncology salaries in 2026 are rising because the strongest candidates can choose between startups, pharma, medtech and AI scaleups. Competitive offers combine salary, equity, mission, autonomy and evidence that the company can execute clinically and commercially.

Hiring Strategy Recommendations for AI Oncology Startups

Hiring strategy should be built before a funding round closes, not after the announcement. The market moves too quickly for reactive recruitment, especially when a company needs senior leadership, bioinformatics, regulatory affairs or computational pathology talent within a defined clinical milestone window.

Startups should build passive candidate pipelines before hiring becomes urgent. This means mapping Cambridge, Paris, Barcelona, Leuven, London and relevant cross-border talent pools ahead of the mandate. Warm networks matter because senior oncology AI candidates are often not applying for roles publicly.

Mission should be central to the proposition. Clinical impact is one of the few credible differentiators startups have against pharma and big tech. Candidates need to understand the cancer indication, patient benefit, data advantage and why the company’s approach could change diagnostics or treatment decisions.

Equity should be structured and explained properly. Candidates increasingly ask sophisticated questions about vesting, dilution, option exercise costs and investor composition. Vague equity communication can undermine trust, particularly with executives and senior engineers.

Interview processes must be shorter and more evidence-based. A strong process can include a founder or executive screen, a technical or scientific assessment, a regulatory or clinical discussion where relevant, and a final leadership conversation. Six or seven stages will often lose candidates with multiple offers. Candidate assessment should test the real risks of the role, not generic intelligence.

Specialist recruiters add value when they already understand the market. For AI oncology startup recruitment in Europe, that means credible outreach to passive candidates, cross-border hiring execution, salary benchmarking and the ability to distinguish a good AI profile from a profile that can operate in oncology and regulated healthcare. Optima Search Europe works across executive search, GTM, digital, IT and specialist technology recruitment, including senior and business-critical roles across European and global markets.

Structured summary: The strongest hiring strategies are proactive, specialised and fast. AI oncology startups should map passive talent early, lead with clinical impact, benchmark compensation accurately and use assessment methods that reflect the scientific, technical and regulatory realities of the role.

Case Study / Scenario

The following representative scenario reflects the type of hiring challenge seen in Series A oncology diagnostics companies.

Client Context

A Cambridge-based Series A AI oncology diagnostics startup was preparing clinical trial activity for a liquid biopsy platform. The board needed four hires within 60 days: a CSO, two Senior Bioinformaticians and a Regulatory Affairs Manager with EU MDR and IVDR awareness.

The internal team had strong scientific credibility but limited bandwidth for cross-border outreach. The most relevant candidates were not active applicants. Many were working in pharma, diagnostics scaleups, academic translational labs or genomics businesses.

Search Process

The process started with European oncology AI talent mapping across Cambridge, London, Paris, Barcelona, Leuven and selected remote-capable markets. Passive outreach was tailored by candidate archetype, with separate messaging for scientific leadership, cancer genomics and regulatory affairs.

Assessment was multi-disciplinary. The CSO evaluation focused on scientific strategy, translational credibility, investor communication and clinical milestone planning. Bioinformatics candidates were assessed for cancer genomics depth, pipeline ownership and cross-functional communication. Regulatory candidates were evaluated for EU MDR, IVDR, CE marking and companion diagnostics awareness.

Timeline and Outcome

The first placement was made in 35 days. All four roles were closed within the 60-day target, allowing clinical trial preparation to remain on schedule. The key success factor was not volume sourcing. It was precise market mapping, passive candidate engagement and a structured assessment process aligned to the startup’s clinical and regulatory milestones.

Structured summary: Series A oncology AI hiring succeeds when the search is built around business-critical milestones. For liquid biopsy and diagnostics companies, recruitment must connect scientific leadership, bioinformatics execution and regulatory readiness within one coordinated process.

Frequently Asked Questions

Which European cities have the most AI oncology startup activity in 2026? Cambridge, Barcelona and Paris are the most visible AI oncology startup hubs in 2026. Cambridge combines cancer research, molecular diagnostics, genomics and spinout activity. Barcelona has strength in genomics, diagnostics and digital health, supported by a strong biomedical ecosystem. Paris is increasingly important for foundation models in biology, computational oncology and translational research. Leuven, London, Manchester and selected Dutch hubs also matter, especially for imaging, medtech and clinical AI. The best hiring strategy is rarely single-city. Most startups need a cross-border approach that maps where each role type is realistically available.

What roles are AI oncology startups in Europe most urgently hiring for? The most urgent roles are computational pathology scientists, ML engineers with oncology domain knowledge, bioinformaticians specialising in cancer genomics, regulatory affairs managers and clinical affairs managers. At leadership level, CSO and VP R&D roles are particularly sensitive because they affect scientific direction, investor confidence and clinical milestone delivery. Demand is strongest for people who can operate across disciplines, for example a bioinformatician who understands assay constraints or an ML engineer who can work with clinical validation requirements. Pure technical skill is rarely enough in oncology AI.

How can early-stage AI oncology startups compete with pharma on compensation? Startups rarely win against pharma on cash alone. They compete through a more complete proposition: meaningful equity, faster decision-making, scientific ownership, visible patient impact and access to senior influence earlier in the company’s growth. Compensation still needs to be credible, especially for senior ML, bioinformatics, regulatory and executive hires. Candidates will benchmark salary, equity, runway and leadership quality. A weak offer narrative can be as damaging as a low number. Startups should prepare compensation ranges before outreach and be transparent about equity mechanics.

How does EU MDR affect hiring for companion diagnostic AI startups in Europe? EU MDR and IVDR increase demand for candidates who understand regulated diagnostics, clinical evidence, quality management, risk management and CE marking. For companion diagnostic AI startups, the hiring requirement often extends beyond a standard regulatory affairs profile. The company may need people who can work with clinical teams, software engineers, assay developers and external notified bodies. This affects role design, interview assessment and salary benchmarking. It also means regulatory hiring should start early, not just before submission deadlines. Delayed regulatory recruitment can slow validation and commercial readiness.

What is the typical hiring timeline for senior roles at AI oncology startups in Europe? For senior technical or regulatory roles, a realistic timeline is usually six to ten weeks if the brief is clear and the compensation range is competitive. Executive searches for CSO, VP R&D or senior clinical leadership may take eight to twelve weeks, particularly if the search is confidential or cross-border. Timelines lengthen when the role is poorly defined, equity is unclear or interview stages are excessive. Startups with warm passive pipelines, fast founder involvement and structured candidate assessment can move faster without sacrificing quality.

Conclusion & Strategic Positioning

European AI oncology is entering a high-growth, high-competition hiring phase. The companies most likely to scale in 2026 will be those that can recruit across AI, oncology, diagnostics, clinical validation and regulation before talent bottlenecks slow execution.

For founders, CTOs, HR leaders and boards, recruitment is now part of the clinical and commercial strategy. The right CSO, bioinformatician, ML engineer or regulatory leader can affect funding confidence, validation timelines, partnership readiness and market credibility.

Optima Search Europe supports specialist recruitment, executive search, cross-border hiring, salary benchmarking and senior candidate engagement for business-critical roles across Europe and global markets. For AI oncology startups preparing Series A or Series B hiring plans, the priority is clear: map the market early, assess precisely and engage passive candidates before competitors do.